Organon Finalizes Dermavant Acquisition, Including VTAMA® Cream

Organon, a global healthcare company focusing on improving women's health, has announced the completion of its acquisition of Dermavant Sciences Ltd. from Roivant. Dermavant is known for developing and commercializing innovative treatments in the field of immuno-dermatology. The acquisition enhances Organon's dermatology capabilities in the U.S. with a novel nonbiologic and non-steroidal topical treatment.

The key product from this acquisition is VTAMA® (tapinarof) cream, 1%, a nonbiologic and non-steroidal topical therapy approved by the U.S. Food and Drug Administration (FDA) for treating plaque psoriasis in adults. This product has no safety label warnings or restrictions concerning its use. The FDA is currently reviewing a supplemental New Drug Application (sNDA) for VTAMA cream as a potential treatment for atopic dermatitis in adults and children aged two years and older, with a decision expected in the fourth quarter of 2024.

Plaque psoriasis and atopic dermatitis, commonly known as eczema, are widespread inflammatory skin conditions affecting millions globally. Psoriasis significantly reduces the quality of life, while atopic dermatitis presents a higher disease burden, particularly for women.

Kevin Ali, CEO of Organon, expressed enthusiasm about the acquisition. He emphasized that innovative treatments like VTAMA are crucial for the future of dermatology. The acquisition will allow Organon to expand its existing portfolio of established dermatology brands and biosimilars. Integrating Dermavant's expertise into Organon's U.S. operations marks a significant step forward in providing better treatment options for patients with chronic skin conditions like plaque psoriasis and potentially atopic dermatitis in the future.

Mayukh Sukhatme, MD, President and Chief Investment Officer of Roivant, also commented on the successful acquisition. He highlighted the partnership between Organon and Roivant as a significant step towards addressing patient needs. Sukhatme believes that Organon's strong global commercial presence will maximize VTAMA's impact for patients worldwide. The partnership underscores Roivant's capability to form valuable collaborations in the pharmaceutical industry.

VTAMA cream is a non-steroidal, once-daily topical treatment. Its safety and effectiveness were evaluated in randomized, double-blind, vehicle-controlled trials, PSOARING-1 and PSOARING-2 for plaque psoriasis. The safety and efficacy of VTAMA for treating atopic dermatitis were also evaluated in ADORING-1 and ADORING-2 Phase III clinical studies, and it is currently under FDA review.

Organon is dedicated to improving women's health throughout their lives. The company's diverse portfolio includes over 60 medicines and products spanning women's health, biosimilars, and various therapeutic areas. Organon is committed to investing in innovative solutions and research to drive future growth in women's health and biosimilars. The company also focuses on forming collaborations with biopharmaceutical partners to commercialize their products in fast-growing international markets.

Organon operates with a significant global presence and approximately 10,000 employees. Its headquarters are located in Jersey City, New Jersey.

In conclusion, Organon's acquisition of Dermavant represents a strategic move to enhance its dermatology portfolio and provide better treatment options for chronic skin conditions. The integration of VTAMA cream into Organon's offerings is expected to benefit millions of patients suffering from plaque psoriasis and potentially atopic dermatitis in the future.